Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

rable" responses with improved tolerability, even in patients who had stopped responding to either drug when used alone. The data presented this week showed a 100 percent response rate in newly diagnosed patients and a 68 percent response rate in relapsed patients.

"The number of options available to treat myeloma patients today is growing with positive results from mature studies, as well as preliminary results from smaller trials," said Brian G.M. Durie, M.D. chairman and co- founder of the IMF. "What we are learning from using these novel combinations in myeloma is so promising that our findings may become applicable to many malignancies including lung, ovarian and other cancers. The progress we've begun in myeloma is encouraging for all cancer patients around the world."

Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 135,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses in four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 120 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank On A Cure(R), a unique gene bank to advance myeloma research. The IMF can be reached at (800) 452-CURE or http://www.myeloma.org, and in Spanish at http://www.myelomala.org.

Contact: Stephen Gendel

              The International Myel
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
(Date:9/23/2014)... 23, 2014   COTA, Inc. today announced ... million Series A funding round led by Horizon Healthcare ... the first big data platform designed by practicing oncologists ... for cancer care in support of healthcare,s new value-based ... expand development of the COTA platform, hire biostatisticians, outcome ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
...  ZHUHAI, China, Oct. 24, 2011 ... a leading global manufacturer of electronic medical devices ... worldwide technology licensing agreement and the launch of ...  new generation of modular patient monitors. The agreement ...
... Mont., Oct. 24, 2011 Bacterin International ... leader in the development of revolutionary bone graft material and ... at the Singular Research,s Sixth Annual ,Best of the Uncovereds, ... Boulevard Hotel in Los Angeles, California. Bacterin,s chairman ...
Cached Medicine Technology:Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 2Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 3Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 4Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 5Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 6Bacterin to Present at Sixth Annual Singular Research 'Best of the Uncovereds' Conference on October 26, 2011 2
(Date:9/23/2014)... Sinica, the preeminent academic institution in the Republic ... agreement to develop a unique educational and scientific ... to translate innovative technologies and commercially relevant discoveries ... Sept.12 in Taipei by Harris Lewin, vice chancellor ... Wong of Academia Sinica. The program will be ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 As ... taken before making a purchase. It’s difficult to trust ... it’s easy for them to manipulate their customers into ... this dilemma, but they tend to lack in depth ... Health Reports was founded to fix this issue ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... unapproved prescription drugs is growing, so doctors need ... Food and Drug Administration warned Tuesday. In ... so widespread that it has launched a program ... and administrators about proper drug purchasing procedures. The ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Finding Affordable Care: Asking the Right Question is Key 2
... Alan Mozes HealthDay Reporter , TUESDAY, Dec. 20 ... wriggling) competition in cleaning troublesome wounds: maggots. To the ... suggests that bagging up live, sterile fly larvae in tightly ... be a quick, safe and effective way to clear ...
... Gordon HealthDay Reporter , TUESDAY, Dec. 20 (HealthDay ... a doctor should decide if complications are severe enough to ... (ADA) says. In a new position statement published in ... advises against blanket bans or restrictions. Instead, it recommends that ...
... accounts for the majority of all thyroid malignancies, which primarily ... nodes in the neck in these cancer patients may help ... thyroid cancer metastasizes, lymph nodes in the neck may be ... not be detected by ultrasounds done before surgery to remove ...
... 20 (HealthDay News) -- Increasing concentrations of two ... samples collected in the Great Lakes region between ... The chemicals are used to reduce flammability in ... and polyurethane foams. They are 2-ethylhexyl tetrabromobenzoate [TBB] ...
... 20, 2011Women who are at risk for breast cancer may ... has found. The majority of women with hereditary breast ... or BRCA2 genes, which normally suppress the growth of breast ... at St. Michael,s Hospital, said his research team was surprised ...
... HealthDay Reporter , MONDAY, Dec. 19 (HealthDay News) -- ... likely to develop inflammatory bowel disease such as Crohn,s disease ... according to a new long-term study. Endometriosis ... grows outside of the uterus. Symptoms include abdominal pain, ...
Cached Medicine News:Health News:Maggots Quickly Clean Up Wounds, Study Shows 2Health News:Maggots Quickly Clean Up Wounds, Study Shows 3Health News:Driving Isn't An Issue for Most People With Diabetes 2Health News:Driving Isn't An Issue for Most People With Diabetes 3Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 2Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 3Health News:Buildup of Newer Flame Retardants Concerns Scientists 2Health News:Breast cancer and heart disease may have common roots 2Health News:Endometriosis Tied to Higher Risk of Crohn's, Colitis 2
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Medicine Products: